| Literature DB >> 34117999 |
Guijuan Xie1,2, Bo Zhao2,3, Xun Wang1,2, Liang Bao1,2, Yiming Xu1,2, Xian Ren1,2, Jiali Ji1,2, Ting He1,2, Hongqing Zhao4,5.
Abstract
INTRODUCTION: We aimed to explore the real-world clinical application value and challenges of metagenomic next-generation sequencing (mNGS) for pulmonary infection diagnosis.Entities:
Keywords: Application; Bronchoalveolar lavage fluid (BALF); Bronchoscopy; Clinical diagnosis; Etiology; Metagenomic next-generation sequencing (mNGS); Mixed infection; Pulmonary infection; Transbronchial lung biopsy (TBLB)
Year: 2021 PMID: 34117999 PMCID: PMC8322361 DOI: 10.1007/s40121-021-00476-w
Source DB: PubMed Journal: Infect Dis Ther ISSN: 2193-6382
Baseline characteristics of 140 patients
| Count | Percentage | |
|---|---|---|
| Gender | ||
| Male | 62 | 44.28 |
| Female | 78 | 55.72 |
| Age (years) | ||
| ≤ 40 | 18 | 12.86 |
| > 40, ≤ 70 | 86 | 61.43 |
| > 70 | 36 | 25.71 |
| Basic illness | ||
| Bronchiectasis | 14 | 10.00 |
| Chronic obstructive pulmonary disease | 5 | 3.57 |
| Previous history of tuberculosis | 7 | 5.00 |
| Bronchial asthma | 1 | 0.71 |
| Lung cancer | 7 | 5.00 |
| Diabetes | 23 | 16.43 |
| Connective tissue disease | 16 | 11.43 |
| Extrapulmonary malignancies | 10 | 7.14 |
| Sample type | ||
| BALF | 119 | 85.00 |
| Lung tissue | 9 | 6.43 |
| Blood | 5 | 3.57 |
| Pleural effusion | 6 | 4.29 |
| Sputum | 1 | 0.71 |
| Chest CT scan | ||
| Bilateral | 89 | 63.57 |
| Unilateral | 51 | 36.43 |
BALF bronchoalveolar lavage fluid, CT computerized tomography
Fig. 1Concordance between metagenomic next-generation sequencing (mNGS) and conventional testing. Both+, results of mNGS and conventional testing were both positive; Both−, results of mNGS and conventional testing were both negative; mNGS+, only the mNGS result was positive, conventional testing was not; only conventional testing+, only the conventional testing result was positive, mNGS was not
Fig. 2Species distribution of a Gram-positive bacteria, b Gram-negative bacteria, c fungi, d viruses, e other pathogens (Mycoplasma, Chlamydia psittaci, M. tuberculosis) detected by mNGS
Fig. 3The overlap of positivity between mNGS and conventional testing for fungi and bacteria. Both+, results of mNGS and conventional testing were both positive; mNGS+, only the mNGS result was positive, conventional testing was not; conventional testing+, only the conventional testing result was positive, mNGS was not
Comparison of clinical characteristics between mixed and single pulmonary infection
| Mixed infection | Single infection | ||
|---|---|---|---|
| Characteristics | |||
| Age, years | 60.15 ± 15.90 | 58.45 ± 13.55 | 0.54 |
| Male, | 31 (47.00%) | 31 (60.78%) | 0.28 |
| Female, | 35 (53.00%) | 20 (39.21%) | 0.57 |
| Laboratory parameters | |||
| WBC, (3.5–9.5) × 109/L | 7.61 ± 3.55 | 6.67 ± 3.78 | 0.17 |
| Neutrophil, (1.8–6.3) × 109/L | 5.38 ± 3.30 | 4.54 ± 3.51 | 0.19 |
| Lymphocyte, (1.1–3.2) × 109/L | 1.44 ± 0.67 | 1.46 ± 0.64 | 0.83 |
| CRP, (0–8) mg/L | 38.94 ± 51.74 | 24.33 ± 37.61 | 0.09 |
| PCT, (0–0.1) ng/L | 0.36 ± 1.10 | 0.24 ± 0.60 | 0.51 |
| Presenting symptoms or signs | |||
| Fever, | 22 (33.30%) | 18 (35.20%) | 0.65 |
| Cough, | 54 (81.80%) | 39 (76.47%) | 0.29 |
| Thoracalgia, | 20 (30.30%) | 18 (35.29%) | 0.29 |
| Use of glucocorticoids, | 9 (13.60%) | 9 (17.65%) | 0.39 |
| Underlying pulmonary disease | |||
| Bronchiectasis, | 7 (10.60%) | 3 (5.88%) | 0.31 |
| COPD, | 2 (3.00%) | 2 (3.92%) | 0.57 |
| Previous history of tuberculosis, | 5 (7.60%) | 1 (1.96%) | 0.19 |
| Bronchial asthma, | – | 1 (1.96%) | NA |
| Lung cancer, | 4 (6.10%) | 3 (5.88%) | 0.64 |
| Underlying extrapulmonary disease | |||
| Diabetes, | 15 (22.70%) | 4 (7.84%) | 0.03 |
| Connective tissue disease, | 11 (16.70%) | 5 (9.80%) | 0.24 |
| Malignant tumor, | 4 (6.10%) | 4 (7.84%) | 0.47 |
| Time from admission to test (day) | 3.97 ± 3.00 | 4.69 ± 3.83 | 0.26 |
| Chest CT scan (bilateral), | 43 (65.20%) | 30 (60.78%) | 0.41 |
WBC white blood cell count, CRP C-reactive protein, PCT procalcitonin, COPD chronic obstructive pulmonary disease, CT computerized tomography
Fig. 4Mixed infections for various pathogens detected by mNGS and conventional test
Performance of mNGS and conventional testing in diagnosis of pulmonary infection
| Diagnostic testing | Sensitivity % | Specificity % | PPV % | NPV % |
|---|---|---|---|---|
| mNGS | 89.17 (83.61–94.73) | 75.00 (63.48–86.52) | 95.54 | 53.57 |
| Conventional laboratory-based diagnostic testing | 50.00 (40.98–59.02) | 81.82 (65.70–97.94) | 93.65 | 23.38 |
95% CI 95% confidence intervals, PPV positive predictive value, NPV negative predictive value
| Pulmonary infections remain important causes of morbidity and mortality in the world. Improved diagnostic methods with better sensitivity, speed, and spectrum for pathogen detection are urgently needed. |
| We aimed to explore the real-world clinical application value and challenges of metagenomic next-generation sequencing (mNGS) for pulmonary infection diagnosis. |
| Significant differences were noticed in the positive detection rates of pathogens between mNGS and conventional diagnostic testing (115/140, 82.14% vs 50/140, 35.71%, |
| mNGS is a valuable tool for the detection of pulmonary infections, especially mixed pulmonary infections. There is still a lot of work to be done in interpreting the mNGS reports, because both clinical judgment and literature analysis strategy need to be refined. |